NCT04116528.

Study name	Opiate Suicide Study in Patients With Major Depression (AFSP)
Methods	RCT
Participants	Diagnosed with Major Depressive Disorder (MDD), single or recurrent, and currently experiencing a Major Depressive Episode (MDE) of at least eight weeks in duration, prior to screening, according to the criteria defined in the Diagnosis and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision(DSM‐IV‐TR™).
Interventions	Ketamine Every eligible participant will receive 0.5mg/kg IV given over 40 minutes Active Comparator: Buprenorphine or Placebo Buprenorphine or placebo once daily for 4 weeks
Outcomes	Beck Suicidal Ideation Scale total score opioid activity of ketamine as well as buprenorphine Serum prolactin level Pupillometry
Starting date	August 1, 2020
Contact information	jhawk@stanford.edu
Notes	NCT04116528